Summit Therapeutics (SMMT)
- Cash used, 12 months
- $527M12 months to Sep 30, 2026 (10-Q)
- Net cash
- $630Mat Sep 30, 2026
- Worst fall since listing
- −95.8%Sep 11, 2017 to Dec 1, 2022; back to that high in Sep 2024
THE FULL STORY Summit Therapeutics: One Man, One Drug and a $500 Million Check
About the company
The Long View
What the filings say about the story, dilution and cash runway.
No Long View yet. Request one →
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for Summit Therapeutics, FY2020–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $0.9M in FY2020 to $0.7M in FY2022.
Free cash flow was positive in 0 of the 6 years shown; FY2025: −$324M.
Margins
Margins are not charted: in FY2022 the operating loss (−$72M) was larger than revenue ($0.7M). The table has each year's figures.
Diluted share count
The diluted share count rose 653% from FY2020 to FY2025, to 748M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | — | — | −$1.1B | −$323M | $0.7M | −$324M |
| FY2024 | $0 | — | — | −$221M | −$142M | $0.1M | −$142M |
| FY2023 | $0 | — | — | −$615M | −$77M | $0.1M | −$77M |
| FY2022 | $0.7M | — | −10225% | −$79M | −$42M | $0.6M | −$42M |
| FY2021 | $2M | — | −4764% | −$89M | −$73M | $0.3M | −$73M |
| FY2020 | $0.9M | — | −6185% | −$53M | −$48M | $0.4M | −$49M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 748M | $713M | — | $732M | — | — |
| FY2024 | 719M | $412M | — | $51M | — | — |
| FY2023 | 620M | $186M | $100M | $14M | — | — |
| FY2022 | 193M | $349M | $514M | $12M | — | — |
| FY2021 | 132M | $72M | — | $13M | — | — |
| FY2020 | 99M | $66M | — | $2M | $0 | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 18, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Years before the company changed its fiscal year-end are left out (the last one ended 2019-01-31), so every year shown covers the same 12 months.
- Diluted shares are restated to the current share basis (stock splits or reverse splits), chaining year-over-year changes reported in each 10-K.
Returns by year
| Year | SMMT | S&P 500 |
|---|---|---|
| 2019 | +39.1% | +31.5% |
| 2020 | +193.8% | +18.4% |
| 2021 | −42.8% | +28.7% |
| 2022 | +58.0% | −18.1% |
| 2023 | −38.6% | +26.3% |
| 2024 | +583.7% | +25.0% |
| 2025 | −2.0% | +17.9% |
| 2026 to date | −39.6% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.